Compare PYPD & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PYPD | IAF |
|---|---|---|
| Founded | 2008 | 1985 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.0M | 111.6M |
| IPO Year | 2014 | N/A |
| Metric | PYPD | IAF |
|---|---|---|
| Price | $6.55 | $11.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 193.8K | 36.3K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.44% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.50 | $11.63 |
| 52 Week High | $7.15 | $14.54 |
| Indicator | PYPD | IAF |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 26.97 |
| Support Level | $4.26 | N/A |
| Resistance Level | $7.15 | $12.84 |
| Average True Range (ATR) | 0.52 | 0.23 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 64.65 | 3.08 |
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Abrdn Australia Equity Fund Inc is a non-diversified closed-end management investment company. The Fund's principal investment objective is long-term capital appreciation through investment in equity securities of Australian companies listed on the Australian Stock Exchange Limited (ASX). Its secondary objective is current income, which is expected to be derived from dividends and interest on Australian corporate and governmental securities.